EVMN · NYSE
Evommune (EVMN) Stock Price & Fundamentals
Evommune (EVMN) closed at $1,394.89 on Oct 9, 2026, up 0.83% from the previous close of $1,383.46.
Share price, past year
1Y +45.01%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,394.89 |
| Sep 30, 2026 | $1,388.47 |
| Aug 31, 2026 | $1,394.61 |
| Jul 31, 2026 | $1,365.59 |
| Jun 30, 2026 | $1,327.40 |
| May 29, 2026 | $1,269.69 |
| Apr 30, 2026 | $1,237.07 |
| Mar 31, 2026 | $1,140.43 |
| Feb 27, 2026 | $1,128.19 |
| Jan 30, 2026 | $1,080.21 |
| Dec 31, 2025 | $1,071.79 |
| Nov 28, 2025 | $1,026.08 |
| Oct 31, 2025 | $968.63 |
Key statistics
- Market cap
- $50.61B
- P/E (TTM)
- 252.2
- EPS (TTM)
- $5.53
- Revenue (TTM)
- $10.00M
- Net income (TTM)
- −$94.67M
- Shares outstanding
- 36.3M
- Dividend yield
- —
- 52-week range
- $957.97 – $1,440.13
Evommune's market cap is $50.61B, based on a share price of $1,394.89 and 36.3M shares outstanding as of Jun 30, 2026.
Financials
Evommune reported revenue of $13.00M for fiscal 2025, up 85.71% from fiscal 2024.
Evommune reported a net loss of $68.87M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $13.00M | +85.7% | −$68.87M | −529.8% | −$11.22 | −$76.68M |
| FY2024ended Dec 31, 2024 | $7.00M | — | −$66.81M | −954.4% | −$45.29 | −$58.28M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$32.25M | −$0.89 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$21.67M | −$0.64 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$28.27M | $15.13 |
| Q3 FY2025ended Sep 30, 2025 | $10.00M | −$12.48M | −$8.07 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$13.57M | −$8.80 |
| Q1 FY2025ended Mar 31, 2025 | $3.00M | −$14.56M | −$9.48 |
Company profile
- Name
- Evommune, Inc.
- Ticker
- EVMN
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1891 Page Mill Rd, Palo Alto, CA
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002044725
Recent SEC filings
- Oct 1, 2026
- Sep 23, 2026
- Sep 15, 2026
- Sep 9, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 30, 2026
- Jun 29, 2026
Frequently asked questions
What is Evommune's stock price?
Evommune (EVMN) closed at $1,394.89 on Oct 9, 2026, up 0.83% from the previous close of $1,383.46.
What is Evommune's market cap?
Evommune's market cap is $50.61B, based on a share price of $1,394.89 and 36.3M shares outstanding as of Jun 30, 2026.
How much revenue does Evommune make?
Evommune reported revenue of $13.00M for fiscal 2025, up 85.71% from fiscal 2024.
What is EVMN's P/E ratio?
Evommune's price-to-earnings ratio is 252.2, based on trailing twelve-month diluted EPS of $5.53.
Does Evommune pay a dividend?
Evommune's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Evommune, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures